nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—CYP2C8—Mometasone—systemic scleroderma	0.153	0.209	CbGbCtD
Repaglinide—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.144	0.196	CbGbCtD
Repaglinide—ALB—Captopril—systemic scleroderma	0.1	0.136	CbGbCtD
Repaglinide—ALB—Mycophenolate mofetil—systemic scleroderma	0.0789	0.107	CbGbCtD
Repaglinide—ALB—Prednisone—systemic scleroderma	0.0631	0.0859	CbGbCtD
Repaglinide—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.061	0.083	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—systemic scleroderma	0.0578	0.0787	CbGbCtD
Repaglinide—ALB—Methotrexate—systemic scleroderma	0.0316	0.0431	CbGbCtD
Repaglinide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0247	0.0337	CbGbCtD
Repaglinide—CYP3A4—Prednisone—systemic scleroderma	0.0198	0.0269	CbGbCtD
Repaglinide—PPARG—dermis—systemic scleroderma	0.011	0.32	CbGeAlD
Repaglinide—PPARG—artery—systemic scleroderma	0.00397	0.116	CbGeAlD
Repaglinide—PPARG—endothelium—systemic scleroderma	0.00335	0.0976	CbGeAlD
Repaglinide—PPARG—blood vessel—systemic scleroderma	0.00309	0.09	CbGeAlD
Repaglinide—ABCC8—smooth muscle tissue—systemic scleroderma	0.0019	0.0553	CbGeAlD
Repaglinide—PPARG—connective tissue—systemic scleroderma	0.00159	0.0462	CbGeAlD
Repaglinide—KCNJ11—tendon—systemic scleroderma	0.00155	0.0451	CbGeAlD
Repaglinide—PPARG—smooth muscle tissue—systemic scleroderma	0.00145	0.0422	CbGeAlD
Repaglinide—PPARG—skin of body—systemic scleroderma	0.00143	0.0417	CbGeAlD
Repaglinide—SLCO1B1—digestive system—systemic scleroderma	0.00133	0.0386	CbGeAlD
Repaglinide—PPARG—digestive system—systemic scleroderma	0.00115	0.0333	CbGeAlD
Repaglinide—PPARG—tendon—systemic scleroderma	0.00109	0.0317	CbGeAlD
Repaglinide—PPARG—lung—systemic scleroderma	0.000956	0.0278	CbGeAlD
Repaglinide—Malnutrition—Leflunomide—systemic scleroderma	0.000687	0.00297	CcSEcCtD
Repaglinide—Vasculitis—Methotrexate—systemic scleroderma	0.000687	0.00297	CcSEcCtD
Repaglinide—Dyspepsia—Mometasone—systemic scleroderma	0.000682	0.00295	CcSEcCtD
Repaglinide—Anaphylactic shock—Captopril—systemic scleroderma	0.000681	0.00294	CcSEcCtD
Repaglinide—Rhinitis—Lisinopril—systemic scleroderma	0.00068	0.00294	CcSEcCtD
Repaglinide—Hepatitis—Lisinopril—systemic scleroderma	0.000678	0.00293	CcSEcCtD
Repaglinide—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.000673	0.00291	CcSEcCtD
Repaglinide—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00067	0.0029	CcSEcCtD
Repaglinide—Oedema peripheral—Lisinopril—systemic scleroderma	0.000668	0.00289	CcSEcCtD
Repaglinide—Thrombocytopenia—Captopril—systemic scleroderma	0.000666	0.00288	CcSEcCtD
Repaglinide—Alopecia—Mycophenolic acid—systemic scleroderma	0.000666	0.00288	CcSEcCtD
Repaglinide—Back pain—Leflunomide—systemic scleroderma	0.000665	0.00288	CcSEcCtD
Repaglinide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000662	0.00286	CcSEcCtD
Repaglinide—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000656	0.00284	CcSEcCtD
Repaglinide—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.000653	0.00282	CcSEcCtD
Repaglinide—Leukopenia—Azathioprine—systemic scleroderma	0.000651	0.00282	CcSEcCtD
Repaglinide—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.000649	0.00281	CcSEcCtD
Repaglinide—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.000645	0.00279	CcSEcCtD
Repaglinide—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.000644	0.00278	CcSEcCtD
Repaglinide—Cardiac failure congestive—Prednisone—systemic scleroderma	0.000642	0.00278	CcSEcCtD
Repaglinide—Erythema multiforme—Lisinopril—systemic scleroderma	0.000641	0.00277	CcSEcCtD
Repaglinide—Pruritus—Pentoxifylline—systemic scleroderma	0.000635	0.00275	CcSEcCtD
Repaglinide—Back pain—Mycophenolic acid—systemic scleroderma	0.000634	0.00274	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000634	0.00274	CcSEcCtD
Repaglinide—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000626	0.00271	CcSEcCtD
Repaglinide—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.000621	0.00269	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00062	0.00268	CcSEcCtD
Repaglinide—Arthralgia—Azathioprine—systemic scleroderma	0.00062	0.00268	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000615	0.00266	CcSEcCtD
Repaglinide—Leukopenia—Leflunomide—systemic scleroderma	0.000615	0.00266	CcSEcCtD
Repaglinide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000614	0.00266	CcSEcCtD
Repaglinide—Abdominal pain—Mometasone—systemic scleroderma	0.000613	0.00265	CcSEcCtD
Repaglinide—Paraesthesia—Captopril—systemic scleroderma	0.000611	0.00264	CcSEcCtD
Repaglinide—Palpitations—Leflunomide—systemic scleroderma	0.000607	0.00263	CcSEcCtD
Repaglinide—Arrhythmia—Lisinopril—systemic scleroderma	0.000606	0.00262	CcSEcCtD
Repaglinide—Alopecia—Lisinopril—systemic scleroderma	0.0006	0.00259	CcSEcCtD
Repaglinide—Dyspepsia—Captopril—systemic scleroderma	0.000599	0.00259	CcSEcCtD
Repaglinide—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.000596	0.00258	CcSEcCtD
Repaglinide—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.000594	0.00257	CcSEcCtD
Repaglinide—Hypertension—Leflunomide—systemic scleroderma	0.000593	0.00257	CcSEcCtD
Repaglinide—Erythema—Lisinopril—systemic scleroderma	0.000591	0.00255	CcSEcCtD
Repaglinide—Malnutrition—Lisinopril—systemic scleroderma	0.000591	0.00255	CcSEcCtD
Repaglinide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000587	0.00254	CcSEcCtD
Repaglinide—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000586	0.00253	CcSEcCtD
Repaglinide—Arthralgia—Leflunomide—systemic scleroderma	0.000585	0.00253	CcSEcCtD
Repaglinide—Chest pain—Leflunomide—systemic scleroderma	0.000585	0.00253	CcSEcCtD
Repaglinide—Constipation—Captopril—systemic scleroderma	0.000582	0.00252	CcSEcCtD
Repaglinide—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000582	0.00252	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000581	0.00251	CcSEcCtD
Repaglinide—Palpitations—Mycophenolic acid—systemic scleroderma	0.000579	0.00251	CcSEcCtD
Repaglinide—Skin disorder—Azathioprine—systemic scleroderma	0.000577	0.0025	CcSEcCtD
Repaglinide—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000573	0.00248	CcSEcCtD
Repaglinide—Back pain—Lisinopril—systemic scleroderma	0.000571	0.00247	CcSEcCtD
Repaglinide—Vomiting—Pentoxifylline—systemic scleroderma	0.000571	0.00247	CcSEcCtD
Repaglinide—Rash—Pentoxifylline—systemic scleroderma	0.000566	0.00245	CcSEcCtD
Repaglinide—Hypertension—Mycophenolic acid—systemic scleroderma	0.000566	0.00245	CcSEcCtD
Repaglinide—Dermatitis—Pentoxifylline—systemic scleroderma	0.000566	0.00245	CcSEcCtD
Repaglinide—Headache—Pentoxifylline—systemic scleroderma	0.000563	0.00243	CcSEcCtD
Repaglinide—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000561	0.00243	CcSEcCtD
Repaglinide—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000558	0.00241	CcSEcCtD
Repaglinide—Chest pain—Mycophenolic acid—systemic scleroderma	0.000558	0.00241	CcSEcCtD
Repaglinide—Gastrointestinal pain—Captopril—systemic scleroderma	0.000557	0.00241	CcSEcCtD
Repaglinide—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000556	0.0024	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000554	0.0024	CcSEcCtD
Repaglinide—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000552	0.00239	CcSEcCtD
Repaglinide—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000549	0.00238	CcSEcCtD
Repaglinide—Pruritus—Mometasone—systemic scleroderma	0.000548	0.00237	CcSEcCtD
Repaglinide—Skin disorder—Leflunomide—systemic scleroderma	0.000545	0.00236	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000541	0.00234	CcSEcCtD
Repaglinide—Abdominal pain—Captopril—systemic scleroderma	0.000538	0.00233	CcSEcCtD
Repaglinide—Oedema—Mycophenolic acid—systemic scleroderma	0.000535	0.00231	CcSEcCtD
Repaglinide—Nausea—Pentoxifylline—systemic scleroderma	0.000533	0.00231	CcSEcCtD
Repaglinide—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000531	0.0023	CcSEcCtD
Repaglinide—Diarrhoea—Mometasone—systemic scleroderma	0.00053	0.00229	CcSEcCtD
Repaglinide—Leukopenia—Lisinopril—systemic scleroderma	0.000529	0.00229	CcSEcCtD
Repaglinide—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000525	0.00227	CcSEcCtD
Repaglinide—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000524	0.00227	CcSEcCtD
Repaglinide—Palpitations—Lisinopril—systemic scleroderma	0.000522	0.00226	CcSEcCtD
Repaglinide—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00052	0.00225	CcSEcCtD
Repaglinide—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000517	0.00224	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—systemic scleroderma	0.000514	0.00222	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000513	0.00222	CcSEcCtD
Repaglinide—CYP3A4—digestive system—systemic scleroderma	0.000511	0.0149	CbGeAlD
Repaglinide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000511	0.00221	CcSEcCtD
Repaglinide—Paraesthesia—Leflunomide—systemic scleroderma	0.000504	0.00218	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000503	0.00217	CcSEcCtD
Repaglinide—Chest pain—Lisinopril—systemic scleroderma	0.000503	0.00217	CcSEcCtD
Repaglinide—Arthralgia—Lisinopril—systemic scleroderma	0.000503	0.00217	CcSEcCtD
Repaglinide—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000501	0.00216	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000499	0.00216	CcSEcCtD
Repaglinide—Dyspepsia—Leflunomide—systemic scleroderma	0.000494	0.00214	CcSEcCtD
Repaglinide—Pancreatitis—Prednisone—systemic scleroderma	0.000494	0.00213	CcSEcCtD
Repaglinide—Vomiting—Mometasone—systemic scleroderma	0.000493	0.00213	CcSEcCtD
Repaglinide—Rash—Mometasone—systemic scleroderma	0.000489	0.00211	CcSEcCtD
Repaglinide—Dermatitis—Mometasone—systemic scleroderma	0.000488	0.00211	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000488	0.00211	CcSEcCtD
Repaglinide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000486	0.0021	CcSEcCtD
Repaglinide—Headache—Mometasone—systemic scleroderma	0.000485	0.0021	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000484	0.00209	CcSEcCtD
Repaglinide—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000482	0.00208	CcSEcCtD
Repaglinide—Oedema—Lisinopril—systemic scleroderma	0.000482	0.00208	CcSEcCtD
Repaglinide—Pruritus—Captopril—systemic scleroderma	0.000482	0.00208	CcSEcCtD
Repaglinide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000481	0.00208	CcSEcCtD
Repaglinide—Constipation—Leflunomide—systemic scleroderma	0.00048	0.00207	CcSEcCtD
Repaglinide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000472	0.00204	CcSEcCtD
Repaglinide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000471	0.00204	CcSEcCtD
Repaglinide—Abdominal pain—Azathioprine—systemic scleroderma	0.00047	0.00203	CcSEcCtD
Repaglinide—Skin disorder—Lisinopril—systemic scleroderma	0.000468	0.00202	CcSEcCtD
Repaglinide—Diarrhoea—Captopril—systemic scleroderma	0.000466	0.00201	CcSEcCtD
Repaglinide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000463	0.002	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000462	0.002	CcSEcCtD
Repaglinide—Nausea—Mometasone—systemic scleroderma	0.00046	0.00199	CcSEcCtD
Repaglinide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000459	0.00198	CcSEcCtD
Repaglinide—Constipation—Mycophenolic acid—systemic scleroderma	0.000458	0.00198	CcSEcCtD
Repaglinide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000457	0.00198	CcSEcCtD
Repaglinide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000454	0.00196	CcSEcCtD
Repaglinide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000447	0.00193	CcSEcCtD
Repaglinide—Urticaria—Leflunomide—systemic scleroderma	0.000446	0.00193	CcSEcCtD
Repaglinide—Abdominal pain—Leflunomide—systemic scleroderma	0.000443	0.00192	CcSEcCtD
Repaglinide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000442	0.00191	CcSEcCtD
Repaglinide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000441	0.00191	CcSEcCtD
Repaglinide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000441	0.00191	CcSEcCtD
Repaglinide—Myocardial infarction—Prednisone—systemic scleroderma	0.00044	0.0019	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000439	0.0019	CcSEcCtD
Repaglinide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000438	0.00189	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000438	0.00189	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000438	0.00189	CcSEcCtD
Repaglinide—Paraesthesia—Lisinopril—systemic scleroderma	0.000433	0.00187	CcSEcCtD
Repaglinide—Vomiting—Captopril—systemic scleroderma	0.000433	0.00187	CcSEcCtD
Repaglinide—Rash—Captopril—systemic scleroderma	0.000429	0.00186	CcSEcCtD
Repaglinide—Dermatitis—Captopril—systemic scleroderma	0.000429	0.00185	CcSEcCtD
Repaglinide—Headache—Captopril—systemic scleroderma	0.000426	0.00184	CcSEcCtD
Repaglinide—Dyspepsia—Lisinopril—systemic scleroderma	0.000424	0.00183	CcSEcCtD
Repaglinide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000423	0.00183	CcSEcCtD
Repaglinide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000422	0.00183	CcSEcCtD
Repaglinide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000422	0.00183	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000416	0.0018	CcSEcCtD
Repaglinide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000413	0.00179	CcSEcCtD
Repaglinide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000413	0.00179	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—systemic scleroderma	0.000412	0.00178	CcSEcCtD
Repaglinide—Constipation—Lisinopril—systemic scleroderma	0.000412	0.00178	CcSEcCtD
Repaglinide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00041	0.00177	CcSEcCtD
Repaglinide—Diarrhoea—Azathioprine—systemic scleroderma	0.000406	0.00176	CcSEcCtD
Repaglinide—Nausea—Captopril—systemic scleroderma	0.000404	0.00175	CcSEcCtD
Repaglinide—Pruritus—Leflunomide—systemic scleroderma	0.000397	0.00172	CcSEcCtD
Repaglinide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000394	0.0017	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000385	0.00166	CcSEcCtD
Repaglinide—Diarrhoea—Leflunomide—systemic scleroderma	0.000384	0.00166	CcSEcCtD
Repaglinide—Urticaria—Lisinopril—systemic scleroderma	0.000383	0.00166	CcSEcCtD
Repaglinide—Abdominal pain—Lisinopril—systemic scleroderma	0.000381	0.00165	CcSEcCtD
Repaglinide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000379	0.00164	CcSEcCtD
Repaglinide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000379	0.00164	CcSEcCtD
Repaglinide—Vomiting—Azathioprine—systemic scleroderma	0.000378	0.00163	CcSEcCtD
Repaglinide—Eye disorder—Prednisone—systemic scleroderma	0.000377	0.00163	CcSEcCtD
Repaglinide—Rash—Azathioprine—systemic scleroderma	0.000375	0.00162	CcSEcCtD
Repaglinide—Dermatitis—Azathioprine—systemic scleroderma	0.000374	0.00162	CcSEcCtD
Repaglinide—Headache—Azathioprine—systemic scleroderma	0.000372	0.00161	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000372	0.00161	CcSEcCtD
Repaglinide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000372	0.00161	CcSEcCtD
Repaglinide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000366	0.00158	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000365	0.00158	CcSEcCtD
Repaglinide—Immune system disorder—Prednisone—systemic scleroderma	0.000364	0.00157	CcSEcCtD
Repaglinide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000361	0.00156	CcSEcCtD
Repaglinide—Arrhythmia—Prednisone—systemic scleroderma	0.00036	0.00156	CcSEcCtD
Repaglinide—Vomiting—Leflunomide—systemic scleroderma	0.000357	0.00154	CcSEcCtD
Repaglinide—Alopecia—Prednisone—systemic scleroderma	0.000356	0.00154	CcSEcCtD
Repaglinide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000355	0.00154	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000355	0.00153	CcSEcCtD
Repaglinide—Rash—Leflunomide—systemic scleroderma	0.000354	0.00153	CcSEcCtD
Repaglinide—Dermatitis—Leflunomide—systemic scleroderma	0.000353	0.00153	CcSEcCtD
Repaglinide—Nausea—Azathioprine—systemic scleroderma	0.000353	0.00153	CcSEcCtD
Repaglinide—Headache—Leflunomide—systemic scleroderma	0.000351	0.00152	CcSEcCtD
Repaglinide—Erythema—Prednisone—systemic scleroderma	0.000351	0.00152	CcSEcCtD
Repaglinide—Malnutrition—Prednisone—systemic scleroderma	0.000351	0.00152	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000345	0.00149	CcSEcCtD
Repaglinide—Pruritus—Lisinopril—systemic scleroderma	0.000341	0.00147	CcSEcCtD
Repaglinide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00034	0.00147	CcSEcCtD
Repaglinide—Rash—Mycophenolic acid—systemic scleroderma	0.000337	0.00146	CcSEcCtD
Repaglinide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000337	0.00146	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—systemic scleroderma	0.000337	0.00146	CcSEcCtD
Repaglinide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000335	0.00145	CcSEcCtD
Repaglinide—Headache—Mycophenolic acid—systemic scleroderma	0.000335	0.00145	CcSEcCtD
Repaglinide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000334	0.00144	CcSEcCtD
Repaglinide—Nausea—Leflunomide—systemic scleroderma	0.000333	0.00144	CcSEcCtD
Repaglinide—Diarrhoea—Lisinopril—systemic scleroderma	0.00033	0.00143	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—systemic scleroderma	0.000325	0.0014	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000318	0.00138	CcSEcCtD
Repaglinide—Nausea—Mycophenolic acid—systemic scleroderma	0.000318	0.00137	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—systemic scleroderma	0.000315	0.00136	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000313	0.00135	CcSEcCtD
Repaglinide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000311	0.00135	CcSEcCtD
Repaglinide—Vomiting—Lisinopril—systemic scleroderma	0.000306	0.00133	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—systemic scleroderma	0.000304	0.00132	CcSEcCtD
Repaglinide—Rash—Lisinopril—systemic scleroderma	0.000304	0.00131	CcSEcCtD
Repaglinide—Dermatitis—Lisinopril—systemic scleroderma	0.000304	0.00131	CcSEcCtD
Repaglinide—Hypertension—Prednisone—systemic scleroderma	0.000303	0.00131	CcSEcCtD
Repaglinide—Headache—Lisinopril—systemic scleroderma	0.000302	0.00131	CcSEcCtD
Repaglinide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000299	0.00129	CcSEcCtD
Repaglinide—Arthralgia—Prednisone—systemic scleroderma	0.000299	0.00129	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—systemic scleroderma	0.000298	0.00129	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000297	0.00128	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—systemic scleroderma	0.000293	0.00127	CcSEcCtD
Repaglinide—Erythema—Methotrexate—systemic scleroderma	0.000293	0.00127	CcSEcCtD
Repaglinide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000289	0.00125	CcSEcCtD
Repaglinide—Nausea—Lisinopril—systemic scleroderma	0.000286	0.00124	CcSEcCtD
Repaglinide—Oedema—Prednisone—systemic scleroderma	0.000286	0.00124	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000286	0.00124	CcSEcCtD
Repaglinide—Back pain—Methotrexate—systemic scleroderma	0.000284	0.00123	CcSEcCtD
Repaglinide—Skin disorder—Prednisone—systemic scleroderma	0.000278	0.0012	CcSEcCtD
Repaglinide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000269	0.00116	CcSEcCtD
Repaglinide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000266	0.00115	CcSEcCtD
Repaglinide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000266	0.00115	CcSEcCtD
Repaglinide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000265	0.00114	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—systemic scleroderma	0.000262	0.00113	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000261	0.00113	CcSEcCtD
Repaglinide—Paraesthesia—Prednisone—systemic scleroderma	0.000257	0.00111	CcSEcCtD
Repaglinide—Dyspepsia—Prednisone—systemic scleroderma	0.000252	0.00109	CcSEcCtD
Repaglinide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000251	0.00108	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—systemic scleroderma	0.00025	0.00108	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—systemic scleroderma	0.00025	0.00108	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000248	0.00107	CcSEcCtD
Repaglinide—Constipation—Prednisone—systemic scleroderma	0.000245	0.00106	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000239	0.00103	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000234	0.00101	CcSEcCtD
Repaglinide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000234	0.00101	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—systemic scleroderma	0.000232	0.001	CcSEcCtD
Repaglinide—Urticaria—Prednisone—systemic scleroderma	0.000227	0.000983	CcSEcCtD
Repaglinide—Abdominal pain—Prednisone—systemic scleroderma	0.000226	0.000979	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000218	0.000943	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—systemic scleroderma	0.000215	0.000929	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisone—systemic scleroderma	0.000211	0.000912	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—systemic scleroderma	0.000211	0.000911	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000207	0.000893	CcSEcCtD
Repaglinide—Pruritus—Prednisone—systemic scleroderma	0.000203	0.000876	CcSEcCtD
Repaglinide—Diarrhoea—Prednisone—systemic scleroderma	0.000196	0.000847	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000196	0.000846	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—systemic scleroderma	0.00019	0.000822	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—systemic scleroderma	0.000189	0.000818	CcSEcCtD
Repaglinide—Vomiting—Prednisone—systemic scleroderma	0.000182	0.000787	CcSEcCtD
Repaglinide—Rash—Prednisone—systemic scleroderma	0.00018	0.000781	CcSEcCtD
Repaglinide—Dermatitis—Prednisone—systemic scleroderma	0.00018	0.00078	CcSEcCtD
Repaglinide—Headache—Prednisone—systemic scleroderma	0.000179	0.000776	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000176	0.000762	CcSEcCtD
Repaglinide—Nausea—Prednisone—systemic scleroderma	0.00017	0.000735	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—systemic scleroderma	0.000169	0.000732	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—systemic scleroderma	0.000164	0.000708	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—systemic scleroderma	0.000152	0.000658	CcSEcCtD
Repaglinide—Rash—Methotrexate—systemic scleroderma	0.000151	0.000652	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—systemic scleroderma	0.000151	0.000652	CcSEcCtD
Repaglinide—Headache—Methotrexate—systemic scleroderma	0.00015	0.000648	CcSEcCtD
Repaglinide—Nausea—Methotrexate—systemic scleroderma	0.000142	0.000615	CcSEcCtD
